---
title: "Stem Cell Therapy for Chronic Kidney Disease: What the Research Shows and Who May Be a Candidate"
description: "An honest guide to mesenchymal stem cell (MSC) therapy for chronic kidney disease (CKD): what the trials show (including negative ones), our 300 million cell IV protocol and price, kidney-specific risks, and who may be a candidate."
canonical: "https://dreambody.clinic/stem-cell-therapy-chronic-kidney-disease-research/"
---

# Stem Cell Therapy for Chronic Kidney Disease: What the Research Shows and Who May Be a Candidate

Maybe it started with a routine blood test, then a referral to a nephrologist and words like “stage 3” or “stage 4.” Now every lab result feels like a verdict, and the conversation has started to include dialysis or a transplant evaluation. It’s natural to look for anything that might protect the kidney function you still have. This guide covers what’s happening in chronic kidney disease (CKD), what the research on mesenchymal stem cells (MSCs) shows, what our protocol costs, and who may be a candidate.

We’ll be straightforward: MSC therapy for kidney disease is investigational. A few small trials reported encouraging signals, others found no benefit, and nothing here replaces your nephrologist’s care.

## What Happens in Chronic Kidney Disease

Your kidneys filter waste and extra fluid from your blood and help control blood pressure. In CKD, that filtering ability declines over months to years.

Doctors track CKD mainly with two tests:

- **eGFR:** a blood-test estimate of how well your kidneys filter. CKD stages 1 to 5 are based on it; stage 5 (below 15) is kidney failure.
- **Urine albumin or protein:** a sign the filtering barrier is leaking.

The most common causes are diabetes and high blood pressure. Others include glomerulonephritis, lupus nephritis and inherited conditions (see our guide to [hereditary kidney disease](https://dreambody.clinic/kidney-disease-hereditary/)). The cause matters: a result in one kind of kidney disease doesn’t automatically apply to another.

Scarred kidney tissue doesn’t grow back, so the realistic goal is usually to slow further loss.

## What Standard Care Can Do

Depending on your situation, your nephrologist may use:

- **Blood pressure control**, often with an ACE inhibitor or ARB, which also lowers protein leakage
- **SGLT2 inhibitors** and other newer medicines that have been shown in large trials to slow CKD progression in many patients
- **Blood sugar management** if you have diabetes
- **Treatment of complications** such as anemia, and diet guidance
- **Avoiding kidney stressors**, such as certain pain relievers, unless your doctor approves them
- **Planning for dialysis or a transplant** when kidney function becomes advanced

These treatments are backed by large trials. Stem cell therapy is not a replacement for any of them.

Sudden swelling, shortness of breath or very little urine can signal an emergency that needs urgent care at home, not travel.

## How MSCs Are Thought to Work in Kidney Disease

MSCs are best understood as signaling cells. They work mainly through paracrine signaling, releasing proteins and tiny vesicles that influence nearby cells. They don’t turn into new kidney filters.

In animal studies, MSCs lowered inflammation and scarring signals in injured kidneys. But results in mice often turn out smaller, or absent, in people. Our [guide to what stem cells are](https://dreambody.clinic/what-are-stem-cells-plain-language-guide/) covers the science.

## What the Research Shows

The human evidence is small and early. Most studies enrolled fewer than 30 people, many had no comparison group, and most focused on diabetic kidney disease.

### Placebo-controlled trials

- **Packham et al., 2016 (*EBioMedicine*, 30 patients):** Adults with diabetic kidney disease (eGFR 20–50) were randomly assigned to a single IV infusion of 150 million or 300 million donor bone marrow precursor cells, or placebo. No treatment-related serious side effects were reported. At 12 weeks, eGFR trended better than placebo in the 150 million group. The 300 million group’s difference was smaller and not statistically significant.
- **NEPHSTROM trial (Perico et al., *Journal of the American Society of Nephrology* 2023, and *Kidney International Reports* 2026):** Adults with type 2 diabetes and progressing kidney disease received one IV infusion of donor bone marrow MSCs or placebo. In the first group (80 million cells; 12 treated, 4 placebo), eGFR declined more slowly with MSCs over 18 months, but a more accurate measured GFR test showed no significant difference. In the second group (160 million cells; 10 treated, 3 placebo), **neither measure differed from placebo.** The researchers said the trial was too small to draw conclusions about benefit.
- **Deng et al., 2017 (*Annals of the Rheumatic Diseases*, 18 patients):** In severe lupus nephritis, adding 200 million umbilical cord MSCs to standard immunosuppression **showed no benefit over placebo.** Remission: 75% with MSCs vs 83% with placebo. The trial was stopped early.

### Uncontrolled studies

- **Zheng et al., 2022 (*Journal of Cellular and Molecular Medicine*, 12 patients):** People with stage 3b–4 CKD received one IV dose of donor fat-derived MSCs (64 to 320 million cells). eGFR rose in 7 of 12 at 24 weeks, mainly in those starting at 30 or higher. Two people had brief, resolved neurological side effects. There was no control group.
- **Makhlough et al., 2017 and 2018 (*Stem Cell Research & Therapy*; *Cytotherapy*):** Two small studies gave patients’ own bone marrow MSCs by IV (6 people with polycystic kidney disease; 7 with other CKD). Neither reported cell-related side effects, and **neither found a significant change in kidney function.**

### A caution worth knowing

A 2017 case report (Kim et al., *Kidney Research and Clinical Practice*) described a man with stable, advanced CKD whose kidney function dropped sharply a week after an IV infusion of his own fat-derived stem cells at a clinic abroad. He started dialysis three months later. One case doesn’t prove cause, but it’s a reminder that cell therapy isn’t risk-free when kidney function is low.

### What the reviews say

A 2026 meta-analysis (Guo et al., *BMC Nephrology*) pooled the three small randomized trials in diabetic and lupus kidney disease and found an average eGFR difference of about 4.6 points in favor of MSCs, with no increase in serious side effects in the diabetic trials. That’s very few patients with short follow-up, and reviews note that no trial has shown that MSCs delay dialysis or help people already on dialysis.

**In plain language:** MSC infusions have generally been well tolerated in small CKD studies, and a few suggest kidney function may decline more slowly for a while. Others, including the placebo-controlled lupus trial and NEPHSTROM’s higher-dose group, found no clear benefit. No MSC therapy is approved by the U.S. FDA for any kidney disease.

### How our protocol compares

Study doses ranged from about 80 million to 320 million cells, usually as one IV infusion, from bone marrow, fat or umbilical cord. Ours is a single IV infusion of 300 million cells from Wharton’s jelly and placenta. In the one placebo-controlled trial that tested 300 million cells (Packham 2016, a different cell type), the result was weaker than at the lower dose. No published trial has tested our exact approach in CKD, and you should know that before deciding.

## Our Kidney Disease Protocol

Here’s exactly what we offer, as listed on our [kidney disease treatment page](https://dreambody.clinic/kidney-disease-stem-cell-treatment/):

- **300 million MSCs by IV infusion.** Donor (allogeneic) cells from Wharton’s jelly and placenta from healthy, live births, expanded in our on-site, COFEPRIS-licensed lab and tested by third-party, COFEPRIS-authorized labs. Cells leave culture the day before treatment and are given within 24 hours.
- **NAD+ and high-dose vitamin C IV drip**, given after the cell infusion. Our physicians review whether each part of the package is appropriate for your kidney function.
- **Physician-reviewed bloodwork** before treatment
- **Price:** $11,500 USD, all-inclusive for the items above

See our [Certified Stem Cells page](https://dreambody.clinic/certified-stem-cells/) and our [guide to MSC science and quality](https://dreambody.clinic/science-and-quality-of-our-mesenchymal-stem-cells/).

### Your 4-day stay

- **Day 1:** Arrive in Puerto Vallarta and rest at your hotel in Bucerías or nearby.
- **Day 2:** Bloodwork, reviewed by our physicians. Payment is completed at the clinic.
- **Day 3:** Stem cell IV, followed by the IV drip.
- **Day 4:** Fly home.

After you return home, we follow up remotely at 3, 6 and 12 months. Many patients report changes over 3 to 6 months, but results vary and some see little or no benefit. With CKD, your lab trends are the best guide, so keep your nephrologist’s planned tests. See our [travel guide](https://dreambody.clinic/travel-guide-stem-cell-treatment-bucerias/) and [hotel options](https://dreambody.clinic/hotels/).

## Who May Be a Candidate

Every case is reviewed individually by our physicians. You may be a reasonable candidate to discuss MSC therapy with us if you:

- Have a confirmed CKD diagnosis and recent records (eGFR trends, urine protein, medication list, imaging or biopsy if available)
- Have a nephrologist at home who will keep managing your care
- Are stable enough to travel for at least four days
- Understand that results vary and improvement isn’t guaranteed

Our physicians may advise against treatment, or advise waiting, if you have:

- **Cancer within the past five years** (we don’t treat these patients)
- **Kidney failure already treated with dialysis**, where the research doesn’t support benefit
- **A recent rapid drop in kidney function**, fluid overload, high potassium, an active infection, or other problems that make travel or an IV unsafe

**About your medicines:** Don’t stop, skip or change any medicine because you’re considering stem cell therapy. Stopping blood pressure, diabetes or kidney-protective medicines on your own can be dangerous. Any change should be decided by your nephrologist.

## Risks and Side Effects

MSC infusions have generally been well tolerated in kidney studies, but the numbers are small.

- **Fever or headache:** about 1 in 100 of our patients have a mild fever and/or headache for a few hours after treatment or the next day.
- **IV risks:** any IV carries a small risk of infection, bruising, vein irritation or a blood clot. Our pre-treatment bloodwork is part of how we screen for this.
- **Kidney-specific unknowns:** a sharp decline in kidney function after a stem cell infusion has been reported. Long-term data are limited.
- **Travel:** plan hydration and your usual medicines with your nephrologist before you go.

The biggest risk is easy to overlook: delaying proven care, including dialysis or transplant evaluation, hoping stem cells will be enough. Please don’t.

## Questions to Ask Any Clinic

Wherever you go, ask which trials (including negative ones) support the protocol, how the dose was chosen, how cells are tested, and how the clinic works with your nephrologist. See our [guide to choosing a stem cell clinic](https://dreambody.clinic/how-to-choose-a-stem-cell-clinic/).

## Frequently Asked Questions

**Can stem cells make my kidneys normal again?** No study has shown that. Some small trials suggest kidney function may decline more slowly for a while, while others found no difference from placebo. Scarred kidney tissue doesn’t grow back.

**Can stem cell therapy help me avoid dialysis?** No study has shown that MSCs prevent or delay dialysis. If your doctors recommend preparing for dialysis or a transplant, please take that advice seriously.

**I’m already on dialysis. Can I still be treated?** The research doesn’t show benefit on dialysis, and our physicians generally advise against it.

**Does this help with diabetic kidney disease specifically?** Most controlled research is in diabetic kidney disease, and it’s early and mixed. See our [type 2 diabetes guide](https://dreambody.clinic/stem-cell-therapy-type-2-diabetes-research/).

**Will insurance cover it?** Generally not. Many U.S. insurers classify it as experimental.

## Thinking About Your Options?

If you’re wondering whether MSC therapy is worth exploring alongside your kidney care, a free consultation is a good place to start. It’s a conversation, not a commitment. A physician will review your labs and medicines, explain what the research does and doesn’t show, and tell you honestly whether this may make sense for you.

**[Schedule your free consultation](https://dreambody.clinic/contact/)**, call (888) 704-3977, WhatsApp +52 322 232 1055, or email info@dreambodyclinic.net.

---

*Disclaimer: This article is for educational purposes and is not medical advice. Mesenchymal stem cell therapy for chronic kidney disease is investigational and is not approved by the U.S. FDA. Published human evidence is limited and mixed, results vary, and some patients see little or no benefit. Stem cell therapy offers no guarantees and does not replace dialysis, transplantation or your nephrologist’s care. Do not stop or change any medication without talking to your own doctor. Treatment eligibility is decided only after a review of your medical history. Dream Body Clinic is located in Bucerías, Nayarit, Mexico, and operates under the oversight of COFEPRIS, Mexico’s health regulator.*
